Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$25.44
▲ $0.29 (+1.2%)
Market data updated: 09/19 02:23 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$2.64B
Day Range
$25.01 - $25.80
52-Week Range
$8.20 - $28.23
Beta
—
Next Earnings
07.10.2026
Support
$21.23
Resistance
$28.23
NRIX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+197.5% (1Y)
Strengths: 8/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 54.0%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$77.57 vs. price $25.44 (-404.9%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
48
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
58
Value
38
Momentum
54
Risk
48
Sentiment
86
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Nurix Therapeutics has centered on its strategic partnerships and financial momentum, particularly its transformative collaboration with Roche for bexobrutideg, which includes a $700 million upfront payment and significant profit-sharing terms. Analysts, like RBC Capital, have raised the stock price target to $36, citing growing recognition of its STAT6 degrader pipeline and potential in chronic conditions. The company is also preparing for upcoming investor conferences in September, while internal updates include the appointment of a new Chief Human Resources Officer.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Nurix Therapeutics, Inc.. News trend score: 86. Reason: 7 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
37
🎯 Conviction (vs. Emotion)
44
Psychology
45
Fundamentals
30
Technical
54
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+45%
Market Narrative
57
Fundamental Reality
44
Narrative Gap
+13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests that while short‑term momentum is negative, the stock stays far above its 200‑day average, driving a high euphoria score. Modest volume increase, neutral RSI, and baseline volatility keep FOMO and panic‑selling scores low, indicating limited urgency among traders. This may reflect an optimism bias where long‑term valuation outweighs recent weakness, with no strong herding or overconfidence signs. The open question is whether positive news sentiment and the elevated long‑term price can sustain enthusiasm if short‑term decline continues.
Updated: 09/09/2026, 06:26 PM
👥 What the crowd believes
"Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg."
"$10 million milestone payment tied to the first in-human trial of an oral STAT6 degrader in its collaboration with Sanofi."
"RBC Capital analyst raises price target from $33 to $36, maintaining Outperform rating."
"Nurix Therapeutics management to participate in fireside chats at Wells Fargo and Wainwright Healthcare Conferences."
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
Based on his documented principles, Walter Bagehot’s model gives NRIX a perfect score, emphasizing strong liquidity and the ability to survive a credit squeeze, a factor that many other frameworks downplay. Value‑oriented investors such as Benjamin Graham (both defensive and enterprising) and Howard Marks flag the stock as insufficiently cheap or risky, reflected in scores in the low‑40s to high‑20s because it fails key safety‑margin and valuation criteria. Growth‑focused thinkers like Philip Fisher, Peter Lynch, and Charles Mackay assign mid‑range scores, noting some growth potential and emerging crowd excitement but also indicating that the price already incorporates much of that upside. Technical and behavioral analysts such as Jesse Livermore, Jack Schwager, Thorstein Veblen, and Morgan Housel give the lowest marks, citing a lack of clear trend, excessive volatility, and a pattern of growth pursued for its own sake, leading them to recommend staying out.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 64
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 48
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 46
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 46
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 45
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 41
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 33
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 29
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 5 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-340.2%
Net Margin
-314.9%
EBITDA Margin
-329.8%
ROE
-49.1%
ROA
-38.4%
ROIC
—
EPS
-$3.05
Cash
$246.96M
Total Debt
—
Current Ratio
7.02
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$25.44
Estimated Fair Value (DCF)
-$77.57
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-404.9%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-329.33M | $-302.14M |
| 2 | 19.4% | $-393.14M | $-330.90M |
| 3 | 13.8% | $-447.20M | $-345.32M |
| 4 | 8.1% | $-483.53M | $-342.55M |
| 5 | 2.5% | $-495.62M | $-322.12M |
Base FCF (last actual year)
$-263.47M
Terminal Value
$-7.82B
Present Value of Terminal Value
$-5.08B
Enterprise Value
$-6.72B
Net Debt
$0
Equity Value
$-6.72B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$6.22
Tangible Book Value per Share (Tangible NAV)
$6.22
Sentiment based on basic keywords (not AI) — 7 positive, 12 neutral, 1 negative out of the last 20 articles.
ChartMill · 18.9.2026
SeekingAlpha · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 10.9.2026
SeekingAlpha · 10.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
MT Newswires · 25.8.2026
SeekingAlpha · 24.8.2026
GlobeNewswire · 20.8.2026
MT Newswires · 10.8.2026
Benzinga · 10.8.2026
MT Newswires · 10.8.2026
Simply Wall St. · 5.8.2026
Yahoo · 5.8.2026
MT Newswires · 4.8.2026
Nurix Therapeutics, Inc. (NRIX) currently has a StockIQ AI score of 48/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NRIX currently scores 48/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, NRIX's estimated fair value is -$77.57, which is 404.9% below the current price of $25.44. This is one valuation model among several signals in the fair-value category, not a price target.
NRIX's technical score is 54/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 54.0%; Operating margin is stable or improving over time; Current ratio: 7.02.
Based on the real signals StockIQ computed: Estimated fair value: -$77.57 vs. price $25.44 (-404.9%); Operating margin: -340.2% (negative); Net margin: -314.9% (negative).
StockIQ has no recorded dividend payment history for NRIX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 14 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Ring Christine | Open Market Sale | 2.9.2026 | 400 | -400 | $26.64 |
| Ring Christine | Exercise of Derivative Securities | 2.9.2026 | 5,787 | -5,787 | — |
| Ring Christine | Exercise of Derivative Securities | 2.9.2026 | 5,787 | +5,787 | $8.72 |
| Ring Christine | Open Market Sale | 2.9.2026 | 5,387 | -5,387 | $25.69 |
| Hansen Gwenn | Exercise of Derivative Securities | 1.9.2026 | 1,452 | -1,452 | — |
| Hansen Gwenn | Exercise of Derivative Securities | 1.9.2026 | 1,452 | +1,452 | $1.86 |
| Hansen Gwenn | Open Market Sale | 1.9.2026 | 1,452 | -1,452 | $25.47 |
| Hansen Gwenn | Open Market Sale | 5.8.2026 | 4,356 | -4,356 | $25.00 |
| Hansen Gwenn | Exercise of Derivative Securities | 5.8.2026 | 4,356 | -4,356 | — |
| Hansen Gwenn | Exercise of Derivative Securities | 5.8.2026 | 4,356 | +4,356 | $1.86 |
| Hansen Gwenn | Exercise of Derivative Securities | 5.8.2026 | 121,583 | +4,356 | $1.86 |
| Hansen Gwenn | Open Market Sale | 5.8.2026 | 117,227 | -4,356 | $25.00 |
| Hansen Gwenn | Exercise of Derivative Securities | 5.8.2026 | 62,310 | -4,356 | — |
| Hansen Gwenn | Open Market Sale | 4.8.2026 | 1,500 | -1,500 | $23.87 |
| van Houte Hans | Open Market Sale | 4.8.2026 | 2,967 | -2,967 | $24.65 |
| van Houte Hans | Open Market Sale | 4.8.2026 | 1,794 | -1,794 | $23.89 |
| Hansen Gwenn | Open Market Sale | 4.8.2026 | 2,611 | -2,611 | $24.64 |
| van Houte Hans | Open Market Sale | 4.8.2026 | 43,133 | -1,794 | $23.89 |
| van Houte Hans | Open Market Sale | 4.8.2026 | 40,166 | -2,967 | $24.65 |
| Hansen Gwenn | Open Market Sale | 4.8.2026 | 119,838 | -1,500 | $23.87 |
| Hansen Gwenn | Open Market Sale | 4.8.2026 | 117,227 | -2,611 | $24.64 |
| Ring Christine | Open Market Sale | 3.8.2026 | 16,589 | -16,589 | $23.05 |
| Ring Christine | Exercise of Derivative Securities | 3.8.2026 | 5,787 | -5,787 | — |
| Ring Christine | Exercise of Derivative Securities | 3.8.2026 | 5,787 | +5,787 | $8.72 |
| Ring Christine | Exercise of Derivative Securities | 3.8.2026 | 25,699 | +5,787 | $8.72 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
17,950,461 shares short as of 2026-08-31 · vs. 18,351,438 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
49.3% of trading volume this week was short selling, vs. 56.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology